An academic professor discusses how next generation proteomics are employed in their cancer research. The stakeholder defines next generation proteomics as comprehensive and including intact proteins, splicing variants, post-translational modifications, and protein complexes. The stakeholder conducts biomarker discovery, target validation, and therapeutic response monitoring experiments with mass spec. They use in vitro assays and clinical tissue specimens for biomarker discovery and target validation. The stakeholder looks for protein profile differences to determine which cells respond better to treatment for therapeutic response monitoring. The limitations of proteomics are cost, speed, and variability. While mass spec is the most used platform, this stakeholder is also moderately familiar with SomaLogic and Isoplexis.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.